Theranexus SA (ALTHX) - Total Liabilities
Based on the latest financial reports, Theranexus SA (ALTHX) has total liabilities worth €7.64 Million EUR (≈ $8.94 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Theranexus SA - Total Liabilities Trend (2015–2025)
This chart illustrates how Theranexus SA's total liabilities have evolved over time, based on quarterly financial data. See ALTHX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Theranexus SA Competitors by Total Liabilities
The table below lists competitors of Theranexus SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Flagship Minerals Ltd
AU:FLG
|
Australia | AU$1.69 Million |
|
Centara Hotels & Resorts Leasehold Property Fund
BK:CTARAF
|
Thailand | ฿900.00K |
|
Regional Express Holdings Ltd
AU:REX
|
Australia | AU$580.78 Million |
|
Royal Road Minerals Ltd
V:RYR
|
Canada | CA$168.25K |
|
Hanil Forging Industrial Co. Ltd
KQ:024740
|
Korea | ₩119.53 Billion |
|
Equus Energy Ltd
AU:EQU
|
Australia | AU$2.18 Million |
|
Daekyo
KO:019680
|
Korea | ₩297.83 Billion |
|
Polychem Indonesia Tbk
JK:ADMG
|
Indonesia | Rp44.23 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Theranexus SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Theranexus SA worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theranexus SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theranexus SA (2015–2025)
The table below shows the annual total liabilities of Theranexus SA from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.64 Million ≈ $8.94 Million |
+41.64% |
| 2024-12-31 | €5.40 Million ≈ $6.31 Million |
+7.58% |
| 2023-12-31 | €5.02 Million ≈ $5.86 Million |
-20.70% |
| 2022-12-31 | €6.33 Million ≈ $7.40 Million |
-5.70% |
| 2021-12-31 | €6.71 Million ≈ $7.84 Million |
-6.67% |
| 2020-12-31 | €7.19 Million ≈ $8.40 Million |
+33.24% |
| 2019-12-31 | €5.39 Million ≈ $6.31 Million |
-0.83% |
| 2018-12-31 | €5.44 Million ≈ $6.36 Million |
+226.73% |
| 2017-12-31 | €1.66 Million ≈ $1.95 Million |
-40.35% |
| 2016-12-31 | €2.79 Million ≈ $3.26 Million |
+165.91% |
| 2015-12-31 | €1.05 Million ≈ $1.23 Million |
-- |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more